Kalaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Published on August 14, 2025
PALO ALTO, Calif.—Kalaris Therapeutics, Inc. (Nasdaq: KLRS), a clinical-stage biopharmaceutical company developing and commercializing treatments for prevalent retinal diseases, yesterday announced financial results for the second quarter ended June 30, 2025, and provided a business update. The company reported a net loss of $11.4 million for the second quarter compared with a net loss of $5.7 million for the prior-year period. The company did not report quarterly revenue or gross profit figures, according to the announcement.
Continue reading on website
Other news

New study compares the effects of low-level red light with 0.01% atropine treatment on axial length and choroid in myopic children

August 13, 2025
Optometry Times delivers clinical news, practice insights, and research updates by optometrists for optometrists to advance care and patient outcomes.

The National Optometric Association: Looking back to move forward

August 14, 2025
Sherrol A. Reynolds, OD, FAAO, details how NOA's history impacts its vision for the future.